IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 63.74

Change

-0.96 (-1.48)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-09 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.46 (-1.09%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-0.72 (-1.14%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-0.71 (-0.71%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-0.27 (-0.33%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.43 (-2.19%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.52 (-0.53%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.69 (-2.47%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.45 (-1.68%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.19 (-2.16%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.27 (-1.54%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.01% 81% B- 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.01% 81% B- 41% F
Trailing 12 Months  
Capital Gain -2.27% 86% B+ 39% F
Dividend Return 1.00% 88% B+ 21% F
Total Return -1.27% 81% B- 33% F
Trailing 5 Years  
Capital Gain 26.67% 67% D+ 47% F
Dividend Return 9.02% 95% A 20% F
Total Return 35.68% 67% D+ 39% F
Average Annual (5 Year Horizon)  
Capital Gain 2.90% 67% D+ 48% F
Dividend Return 4.28% 67% D+ 44% F
Total Return 1.38% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 14.31% 62% D 67% D+
Risk Adjusted Return 29.91% 67% D+ 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike